Search results
Results from the WOW.Com Content Network
Shown is the incidence of death from any cause or disabling stroke among patients assigned to transcatheter aortic-valve replacement (TAVR) and those assigned to surgical aortic-valve replacement.
Surgical risk, age, perceived life expectancy, and valve durability influence the choice between surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation. The contemporaneous life expectancy after SAVR, in relation to surgical risk and age, is unknown.
This cohort study examines changes in risk-adjusted transcatheter aortic valve replacement (TAVR) outcomes from 2019 to 2022 using data from the Society.
In patients aged 35 to 39 years, the standardized mortality ratio was 51.9 (95% CI, 27.9–96.4) compared with 1.27 (95% CI, 1.22–1.32) in patients >85 years old. The risk of death because of cancer was similar between those who underwent AVR and the general population.
Furthermore, during the first 3 years after aortic valve replacement, the absolute difference in the primary outcome of death or disabling stroke between patients who underwent TAVR compared with surgery remained broadly consistent: year 1 Δ −1.8%, year 2 Δ −2.0%, and year 3 Δ −2.9%.
Transcatheter aortic valve replacement (TAVR) has become an alternative to surgical aortic valve replacement (SAVR) for patients with severe symptomatic aortic stenosis across all risk groups. Surgical risk is defined by The Society of Thoracic Surgeons (STS) predicted risk of mortality (PROM).
Among patients with severe aortic stenosis, transcatheter aortic valve replacement (TAVR) has emerged as a less invasive option for aortic valve replacement. This procedure offers substantial reductions in mortality and improvement in quality of life compared with medical therapy 1 , 2 and at least similar long-term outcomes compared to ...
Frailty, an age-related syndrome of physiologic decline and increased vulnerability to stressors, is associated with adverse health outcomes after surgical or transcatheter aortic valve replacement (TAVR). The prediction of death or worsened functional status within 12 months of intervention is an important feature of shared decision-making.
Background: Several clinical trials have demonstrated non-inferiority of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS) and low to intermediate surgical risk. However, mid-term results are still contentious. Question: Is TAVR superior to SAVR in the mid-term in terms of mortality outcomes or ...
5-year valve academic research consortium-3 outcomes and predictors of mortality in a 10-year Asian transcatheter aortic valve implantation registry J Ong, J Ong National University Heart Centre, Singapore, ... Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and ...